Research and Innovation Charlene’s Research Story – Diabetes Type 1 Charlene Absi, 33, is testing new insulin, monitoring her blood pressure and will have her baby screened for type 1 diabetes risk at Wycombe Hospital, High Wycombe. She was diagnosed aged 20 with type 1 diabetes, where the body loses the ability to produce insulin, which controls the amount of glucose in the blood and causes their levels to become too high. This can cause serious long-term health problems such as stroke. Mrs Absi said: “It is my biggest fear that I will pass this disease on to my child and I will give anything for them not to have it and for them to just live a normal life. Having diabetes just means constant monitoring. You don’t get a day off, you can’t just do anything on a whim, everything you do has consequences with diabetes. It was difficult when I was first diagnosed because I didn’t realise how sugary a lot of drinks were and I had to constantly check what I had. I also have to think about which fruits I will eat, as some will have a massive impact on my sugars whereas others won’t.” Mrs Absi, who injects insulin four to eight times a day, said: “When I was diagnosed I had a phobia of needles, so that was
pretty horrifying. It took me a very long time to come to terms with that. When I first found out I was pregnant, I visited the diabetes clinic at my hospital, where my doctor asked if I wanted to take part in a trial and I said ‘yes’ because the type of insulin they were studying could have better results than the type I was already on.” Mrs Absi volunteered for the EXPECT study, which is looking at which insulin is most effective at controlling blood sugar levels in pregnant women with type 1 diabetes. Women on the study are given either insulin Degludec or insulin Detemir, to compare the two. Neither participants nor researchers are told which they will receive, to avoid bias. The BUMP study is looking at whether giving women a blood pressure monitor to use at home can help early detection of pre-eclampsia, which causes high blood pressure and protein in the urine and can be life threatening for the woman and baby if left untreated. Mrs Absi had her blood pressure taken in hospital so she could be compared to those who did it at home. The INGR1D study will involve a sample of her baby’s blood - already collected from newborns for screening - being
Autumn 2019
tested for genetic risk of type 1 diabetes, with the mother’s consent. About 1% of children will have genes which put them at a high risk of type 1 diabetes. Those who have the genes are offered another trial, to see if giving infants daily doses of insulin powder can prevent them from developing the condition. Mrs Absi said, “I’d 100% recommend taking part in research to anyone. To have someone just checking in on you on top of your normal care is amazing. I’ve never been so well looked after and I’d love to stay in research for the rest of my life. I think the more people who get involved in research the better because we’re helping future generations tackle big health issues.”
What is Consent 4 Contact? It’s a registry of Bucks Healthcare NHS Trust patients who are interested in clinical research and want to hear about potential studies, receive this newsletter or support clinical research in some way. The information is held confidentially at the Research & Innovation office & is only used in relation to research at the Trust. Everyone who attends Buckinghamshire Healthcare NHS Trust should have the opportunity to take part in research, helping to improve care and treatments for all, and over 6,000 patients did just that last year.
Pick up a C4C leaflet in any patient waiting area & return it to the Research & Innovation Department at Stoke Mandeville Hospital alternatively, you can complete the online form by following this link: https://www.bhtresearchandinnovation.org/consent-4-contact For further information about research opportunities at Bucks Healthcare NHS Trust call the Research &Innovation Dept on 01296 316065 or see the website www.bhtresearchandinnovation.org You can also follow us on Facebook or Twitter @BHTResearch